JP2007508260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508260A5 JP2007508260A5 JP2006530088A JP2006530088A JP2007508260A5 JP 2007508260 A5 JP2007508260 A5 JP 2007508260A5 JP 2006530088 A JP2006530088 A JP 2006530088A JP 2006530088 A JP2006530088 A JP 2006530088A JP 2007508260 A5 JP2007508260 A5 JP 2007508260A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- propyl
- difluorophenoxy
- chloro
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- -1 8- {4- [3- (2-Chloro-3,6-difluorophenoxy) propyl] phenyl} -5-aza-spiro [2.5] -7-octene-7-carboxylate cyclopropyl- (2, 3-dichlorobenzyl) amide Chemical compound 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- KZRLJNKWCZPQKO-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-5,5-difluoro-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound FC1=CC=C(F)C(OCCCC=2C=CC(=CC=2)C=2C(CNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)(F)F)=C1Cl KZRLJNKWCZPQKO-UHFFFAOYSA-N 0.000 claims 1
- NHKGQZOIJVMGNE-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound C=1C=C(CCCOC=2C(=C(F)C=CC=2F)Cl)C=CC=1C=1C(C)(C)CNCC=1C(=O)N(C1CC1)CC1=CC=CC(Cl)=C1Cl NHKGQZOIJVMGNE-UHFFFAOYSA-N 0.000 claims 1
- UGPQRQQXVSPLPN-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2-methoxy-3-methylpyridin-4-yl)methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound COC1=NC=CC(CN(C2CC2)C(=O)C=2CNCC(C)(C)C=2C=2C=CC(CCCOC=3C(=C(F)C=CC=3F)Cl)=CC=2)=C1C UGPQRQQXVSPLPN-UHFFFAOYSA-N 0.000 claims 1
- ONXNDFLMHFUDGB-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[[2-(2-hydroxypropoxy)-3-methylpyridin-4-yl]methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound CC(O)COC1=NC=CC(CN(C2CC2)C(=O)C=2CNCC(C)(C)C=2C=2C=CC(CCCOC=3C(=C(F)C=CC=3F)Cl)=CC=2)=C1C ONXNDFLMHFUDGB-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000036454 renin-angiotensin system Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Chemical class 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 0 CC1=C(**N)CNCC1(*)* Chemical compound CC1=C(**N)CNCC1(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0311146 | 2003-10-09 | ||
| PCT/EP2004/011088 WO2005040120A1 (en) | 2003-10-09 | 2004-10-05 | Tetrahydropyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508260A JP2007508260A (ja) | 2007-04-05 |
| JP2007508260A5 true JP2007508260A5 (OSRAM) | 2007-11-22 |
Family
ID=34486009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530088A Pending JP2007508260A (ja) | 2003-10-09 | 2004-10-05 | 新規なテトラヒドロピリジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080234305A1 (OSRAM) |
| JP (1) | JP2007508260A (OSRAM) |
| CN (1) | CN1863773A (OSRAM) |
| AU (1) | AU2004283814A1 (OSRAM) |
| CA (1) | CA2540543A1 (OSRAM) |
| WO (1) | WO2005040120A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010323B (zh) * | 2004-08-25 | 2010-06-16 | 埃科特莱茵药品有限公司 | 作为肾素抑制剂的双环壬烯衍生物 |
| GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| WO2007009250A1 (en) * | 2005-07-22 | 2007-01-25 | Merck Frosst Canada Ltd. | Renin inhibitors |
| PE20110117A1 (es) | 2005-12-30 | 2011-03-07 | Novartis Ag | Derivados de 3,5-piridina como inhibidores de renina |
| MX2008011183A (es) * | 2006-03-03 | 2008-09-09 | Actelion Pharmaceuticals Ltd | Aminas primarias como inhibidores de renina. |
| WO2007102127A2 (en) * | 2006-03-08 | 2007-09-13 | Actelion Pharmaceuticals Ltd | New amines |
| EP1908471A1 (en) * | 2006-10-04 | 2008-04-09 | Speedel Experimenta AG | Tetrahydropyridines as renin inhibitors |
| EP2162436A4 (en) | 2007-05-24 | 2010-08-04 | Merck Frosst Canada Ltd | NEW CASE OF RENININHIBITORS |
| CA2689109A1 (en) | 2007-06-25 | 2008-12-31 | Novartis Ag | N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
| AU2008288648A1 (en) | 2007-08-20 | 2009-02-26 | Merck Frosst Canada Ltd. | Renin inhibitors |
| CA2705489A1 (en) * | 2007-12-05 | 2009-06-11 | Basf Se | Pyridylmethyl-sulfonamide compounds |
| MX2010008700A (es) | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
| MX2010012067A (es) | 2008-05-05 | 2010-12-06 | Merck Frosst Canada Ltd | Derivados de 3,4-piperidina sustituida como inhibidores de la renina. |
| AU2009301210B2 (en) | 2008-10-09 | 2014-05-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| CN102209537A (zh) | 2008-11-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 杂环γ分泌酶调节剂 |
| JP5781943B2 (ja) | 2009-01-21 | 2015-09-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
| CN101696187B (zh) * | 2009-09-30 | 2011-09-07 | 徐州工业职业技术学院 | N-取代基-1,2,3,6-四氢吡啶的合成方法 |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| MXPA02008770A (es) * | 2000-03-06 | 2004-09-10 | Acadia Pharm Inc | Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina. |
| US20030013883A1 (en) * | 2000-06-16 | 2003-01-16 | Tamagnan Gilles D. | Tropane analogs binding to monoamine transporters |
| CA2483241C (en) * | 2002-04-29 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Novel diazabicyclononene derivatives |
| CN1662498A (zh) * | 2002-06-27 | 2005-08-31 | 埃科特莱茵药品有限公司 | 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物 |
-
2004
- 2004-10-05 WO PCT/EP2004/011088 patent/WO2005040120A1/en not_active Ceased
- 2004-10-05 JP JP2006530088A patent/JP2007508260A/ja active Pending
- 2004-10-05 CA CA002540543A patent/CA2540543A1/en not_active Abandoned
- 2004-10-05 CN CNA2004800293878A patent/CN1863773A/zh active Pending
- 2004-10-05 AU AU2004283814A patent/AU2004283814A1/en not_active Abandoned
- 2004-10-05 US US10/575,348 patent/US20080234305A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508260A5 (OSRAM) | ||
| CA3009193C (en) | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases | |
| KR102677444B1 (ko) | Cftr 활성을 증가시키는 화합물, 조성물 및 방법 | |
| JP6073464B2 (ja) | 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体 | |
| CN103124727B (zh) | 取代的3-苯基-1,2,4-噁二唑化合物 | |
| HK1250636A1 (zh) | 用於治疗纤维症的短链脱氢酶活性的抑制剂 | |
| JP2008512348A5 (OSRAM) | ||
| SK91695A3 (en) | Five-member heteroaryl-oxazolidinones, their use and medicaments containing them | |
| JP2007505933A5 (OSRAM) | ||
| WO2019101642A1 (en) | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | |
| JP2004517070A5 (OSRAM) | ||
| CN107513073A (zh) | 用于治疗和预防乙型肝炎病毒感染的新的6‑稠合的杂芳基二氢嘧啶 | |
| JP2005532371A5 (OSRAM) | ||
| JP7139568B2 (ja) | ジヒドロピリミジン化合物並びにその調製方法及び使用 | |
| ES2525298T3 (es) | Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares | |
| JP2020525490A (ja) | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染を治療する方法 | |
| RU2006119776A (ru) | Производные бензо{b}{1, 4} диоксепина | |
| JP2012526082A5 (OSRAM) | ||
| EA035465B1 (ru) | 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения | |
| JP5869579B2 (ja) | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 | |
| US20150183786A1 (en) | Bicyclic aza-amides for treatment of psychiatric disorders | |
| RU2005137155A (ru) | Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина | |
| JPS62129282A (ja) | 置換ｎ−〔（４−ピペリジニル）アルキル〕二環式縮合オキサゾ−ル−及びチアゾ−ル−アミン類 | |
| WO2006094763A1 (en) | 3,4,5-substituted piperidine compounds | |
| RU2005137174A (ru) | Азабициклононеновые производные |